The Post-Patent Cliff Tab: Pharma Battered But Still Financially Strong, Says Moody’s
This article was originally published in The Pink Sheet Daily
The patent cliff has battered pharma companies’ financial underpinnings over the past three years, both directly and indirectly, but the industry is still comparatively well endowed to face new macro challenges, ranging from health care reform to pricing pressure and relentless competition, according to Moody’s.
You may also be interested in...
Investor-friendly capital allocation and the rising strength of large biotechs and specialty pharmas have jeopardized Big Pharma’s position of strength in M&A. Analysis by Ernst & Young suggests that industry’s largest companies face unusual challenges – and must adapt to new marketplace realities.
The Big Pharma intends to loosen its leash on its former animal health business come June when Pfizer shareholders will be given an option to swap their shares for Zoetis stock. Meanwhile, Pfizer continues its strategy to shift its focus back to the core pharmaceutical business.
Pfizer’s price of $11.85 billion for selling its pediatric nutritionals business to Nestle came in at the upper end of what most analysts expected. It plans to use the cash it expects to receive – nearly $9 billion – mostly for share repurchases and ‘”tuck-in” M&A.